secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001731122-26-000653
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.01, 9.01, 3.01, 3.02, 3.03, 5.03
LLM model:  deepseek-v4-flash:cloud@v2

Lunai Bioworks completes merger to acquire CNS patent portfolio; issues $20M Series B Preferred Stock
--------------------------------------------------------------------------------

- Acquired CNS patent portfolio via merger; issued $20M Series B Preferred Stock (no cash) to Oncotelic (62.5%) and Pelerin (37.5%).
- Series B convertible at $1.50/share into up to 13.33M common shares; conversion requires stockholder approval under Nasdaq Rule 5635.
- Patents cover Alzheimer's heterocyclic compounds, anti-TGF-beta agents, apomorphine, and intranasal delivery for CNS disorders.
- Closed merger to address Nasdaq stockholders' equity deficiency; also needs bid price compliance by June 4, 2026; Panel decision pending.
- Special meeting May 8 includes reverse split proposal for bid price compliance; conversion approval not on that ballot.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/0001731122-26-000653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112226000653/e7595_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-000653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer